A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy
- Registration Number
- NCT02340221
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This international, multicenter, randomized, double-blinded, placebo-controlled study is designed to compare the efficacy and safety of taselisib + fulvestrant with that of placebo + fulvestrant in postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2)-negative, oncogene that encodes for phosphatidylinositol-4,5-bisphosphate 3-kinase (PIK3CA)-mutant, unresectable, locally advanced or metastatic breast cancer after recurrence or progression during or after an aromatase inhibitor (AI) therapy. There will be a 2:1 randomization to the taselisib arm versus the placebo arm. Enrollment will be enriched for participants with PIK3CA mutant tumors via central testing. The anticipated duration of the study is approximately 3.5 years.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- Female
- Target Recruitment
- 631
- Postmenopausal women with histologically or cytologically confirmed locally advanced or metastatic estrogen receptor (ER) positive breast cancer
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Participants for whom endocrine therapy (example [e.g.], fulvestrant) is recommended and treatment with cytotoxic chemotherapy is not indicated at time of entry into the study
- Radiologic/objective evidence of recurrence or progression to the most recent systemic therapy for breast cancer
- Radiologic/objective evidence of breast cancer recurrence or progression while on or within 12 months of the end of adjuvant treatment with an aromatase inhibitor (AI), or progression while on or within 1 month of the end of prior AI treatment for locally advanced or metastatic breast cancer
- Measurable disease via Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) or non-measurable, evaluable disease with at least one evaluable bone lesion via RECIST v1.1
- Consent to provide a formalin-fixed, paraffin-embedded (FFPE) tumor tissue block (preferred) or a minimum of 20 (25 preferred) freshly cut unstained tumor slides from the most recently collected, available tumor tissue for oncogene that encodes for phosphatidylinositol-4,5-bisphosphate 3-kinase (PIK3CA)-mutation testing
- A valid cobas PIK3CA mutation result by central testing is required
- Adequate hematologic and end-organ function within 28 days prior to treatment initiation
- Human epidermal growth factor receptor 2 (HER2)-positive disease by local laboratory testing (immunohistochemistry 3 positive [IHC 3+] staining or in situ hybridization positive)
- Prior treatment with fulvestrant
- Prior treatment with a phosphatidylinositol 3-kinase (PI3K) inhibitor, mammalian target of rapamycin (mTOR) inhibitor (e.g. everolimus), or protein kinase B (AKT) inhibitor
- Prior anti-cancer therapy within 2 weeks prior to Day 1 of Cycle 1
- Prior radiation therapy within 2 weeks prior to Day 1 of Cycle 1
- All acute treatment-related toxicity must have resolved to Grade less than or equal to (</=) 1 or be deemed stable by the Investigator
- Prior treatment with greater than (>) 1 cytotoxic chemotherapy regimen for metastatic breast cancer
- Concurrent hormone replacement therapy
- Known untreated or active central nervous system (CNS) metastases
- Type 1 or Type 2 diabetes mellitus requiring anti-hyperglycemic medications
- History of inflammatory bowel disease or active bowel inflammation
- Clinically significant cardiac or pulmonary dysfunction
- Clinically significant history of liver disease, including cirrhosis, current alcohol abuse, or current known active infection with human immunodeficiency virus (HIV), hepatitis B or C virus
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Taselisib + Fulvestrant Taselisib Participants received taselisib 4 milligrams (mg) taken orally QD beginning at Cycle 1, Day 1 and fulvestrant 500 mg by IM injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor. Taselisib + Fulvestrant Fulvestrant Participants received taselisib 4 milligrams (mg) taken orally QD beginning at Cycle 1, Day 1 and fulvestrant 500 mg by IM injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor. Placebo + Fulvestrant Placebo Participants received placebo taken orally once daily (QD) beginning at Cycle 1, Day 1, and fulvestrant 500 mg administered by intramuscular (IM) injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor. Placebo + Fulvestrant Fulvestrant Participants received placebo taken orally once daily (QD) beginning at Cycle 1, Day 1, and fulvestrant 500 mg administered by intramuscular (IM) injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor.
- Primary Outcome Measures
Name Time Method PFS as Assessed by Investigator Using RECIST v1.1 at Final Analysis From randomization until the first occurrence of disease progression or death from any cause, whichever occurs earlier (up to approximately 6.2 years) PFS was defined as the time from randomization to disease progression as determined by the investigator with the use of RECIST v1.1 or death due to any cause, whichever occurred earlier. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. For non-target lesions, disease progression was defined as unequivocal progression of existing lesions. The appearance of one or more new lesions was also considered progression.
Progression-Free Survival (PFS) as Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) at Primary Analysis From randomization until the first occurrence of disease progression or death from any cause, whichever occurs earlier (up to the 15 Oct 2017 data cutoff, approximately 2.5 years) PFS was defined as the time from randomization to disease progression as determined by the investigator with the use of RECIST v1.1 or death due to any cause, whichever occurred earlier. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). For non-target lesions, disease progression was defined as unequivocal progression of existing lesions. The appearance of one or more new lesions was also considered progression.
- Secondary Outcome Measures
Name Time Method Percentage of Participants With Objective Response (PR Plus CR), as Assessed Using RECIST v.1.1 at Final Analysis From randomization until the first occurrence of disease progression or death from any cause, whichever occurs earlier (up to approximately 6.2 years) PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels (as applicable to non-target lesions).
PFS as Assessed by BICR Using RECIST v1.1 at Final Analysis From randomization until the first occurrence of disease progression or death from any cause, whichever occurs earlier (up to approximately 6.2 years) PFS was defined as the time from randomization to disease progression as determined by BICR with the use of RECIST v1.1 or death due to any cause, whichever occurred earlier. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. For non-target lesions, disease progression was defined as unequivocal progression of existing lesions. The appearance of one or more new lesions was also considered progression.
Change From Baseline in Modified EORTC Quality of Life Questionnaire Breast Cancer Module 23 (QLQ-BR23) Score Baseline, C2D1 up to C7D1 (each cycle=28 days) EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consists of functional scales (body image, sexual enjoyment, sexual functioning, future perspective \[FP\]) and symptom scales (systemic side effects \[SE\], upset by hair loss, arm symptoms, breast symptoms). Questions used a 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scores were averaged and transformed to a 0-100 scale. Higher scores for the functional scales indicated a higher/better level of functioning/healthy functioning. Higher scores for the symptom scales indicated worse symptoms.
Overall Survival (OS) at Primary Analysis From randomization up to death from any cause (up to the 15 Oct 2017 data cutoff, approximately 2.5 years) OS was defined as the time from the date of randomization to the date of death due to any cause.
OS at Final Analysis From randomization up to death from any cause (up to approximately 6.2 years) OS was defined as the time from the date of randomization to the date of death due to any cause.
Percentage of Participants With Clinical Benefit, as Assessed According to RECIST v1.1 at Primary Analysis From randomization until the first occurrence of disease progression or death from any cause, whichever occurs earlier (up to the 15 Oct 2017 data cutoff, approximately 2.5 years) Clinical benefit was defined as objective response (PR+CR), or no disease progression lasting for more than or equal to (\>/=) 24 weeks since randomization. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels (as applicable to non-target lesions). Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. For non-target lesions, disease progression was defined as unequivocal progression of existing lesions. The appearance of one or more new lesions was also considered progression.
Percentage of Participants With Clinical Benefit, as Assessed According to RECIST v1.1 at Final Analysis From randomization until the first occurrence of disease progression or death from any cause, whichever occurs earlier (up to approximately 6.2 years) Clinical benefit was defined as objective response (PR+CR), or no disease progression lasting for more than or equal to (\>/=) 24 weeks since randomization. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels (as applicable to non-target lesions). Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. For non-target lesions, disease progression was defined as unequivocal progression of existing lesions. The appearance of one or more new lesions was also considered progression.
Percentage of Participants With Objective Response (Partial Response [PR] Plus Complete Response [CR]), as Assessed Using RECIST v.1.1 at Primary Analysis From randomization until the first occurrence of disease progression or death from any cause, whichever occurs earlier (up to the 15 Oct 2017 data cutoff, approximately 2.5 years) PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels (as applicable to non-target lesions).
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) Score Baseline, C2D1 up to C7D1 (each cycle=28 days) The EORTC QLQ-C30 consists of 30 questions that comprise aspects of participant's functioning assessment (physical, emotional, role, cognitive, and social); symptom scales (fatigue; nausea, vomiting, and pain; the global health/quality of life \[QoL\]); and single items (dyspnoea, insomnia, appetite loss, constipation, diarrhoea, and financial difficulties), within a recall period of "the past week." Most questions used a 4-point scale (1=Not at all to 4=Very much; two questions used a 7-point scale (1=Very poor to 7=Excellent). Scores were averaged and transformed to a 0-100 scale; a higher score for Global Qol/functional scales=better level of functioning; a higher score for symptom scale=greater degree of symptoms.
Duration of Objective Response, as Assessed by Investigator Using RECIST v1.1 at Primary Analysis Time from the first occurrence of a documented objective response to the time of the first documented disease progression or death from any cause, whichever occurs earlier (up to the 15 Oct 2017 data cutoff, approximately 2.5 years) Duration of objective response: the time from the first tumor assessment that supported the participant's objective response (CR or PR, whichever was first recorded) to first documented disease progression or death due to any cause, whichever occurred first. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels (as applicable to non-target lesions). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. Disease progression: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. For non-target lesions, disease progression was defined as unequivocal progression of existing lesions. The appearance of one or more new lesions was also considered progression.
Percentage of Participants With Adverse Events at Final Analysis From randomization up to approximately 6.2 years An adverse event was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution.
Minimum Observed Plasma Concentration (Cmin) of Taselisib 1 to 4 hrs post-dose on Cycle 1, Day 1; 0 to 3 hrs pre-dose and 2 to 6 hrs post dose on Cycle 2, Day 1; 0 to 3 hrs pre-dose on Cycle 6, Day 1 (each cycle=28 days) Duration of Objective Response, as Assessed by Investigator Using RECIST v1.1 at Final Analysis Time from the first occurrence of a documented objective response to the time of the first documented disease progression or death from any cause, whichever occurs earlier (up to approximately 6.2 years) Duration of objective response: the time from the first tumor assessment that supported the participant's objective response (CR or PR, whichever was first recorded) to first documented disease progression or death due to any cause, whichever occurred first. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels (as applicable to non-target lesions). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. Disease progression: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. For non-target lesions, disease progression was defined as unequivocal progression of existing lesions. The appearance of one or more new lesions was also considered progression.
PFS as Assessed by Blinded Independent Central Review (BICR) Using RECIST v1.1 at Primary Analysis From randomization until the first occurrence of disease progression or death from any cause, whichever occurs earlier (up to the 15 Oct 2017 data cutoff, approximately 2.5 years) PFS was defined as the time from randomization to disease progression as determined by BICR with the use of RECIST v1.1 or death due to any cause, whichever occurred earlier. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. For non-target lesions, disease progression was defined as unequivocal progression of existing lesions. The appearance of one or more new lesions was also considered progression.
Percentage of Participants With Adverse Events at Primary Analysis From randomization up to the 15 Oct 2017 data cutoff, approximately 2.5 years. An adverse event was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution.
Maximum Observed Plasma Concentration (Cmax) of Taselisib 1 to 4 hours (hrs) post-dose on Cycle (C) 1, Day (D) 1; 0 to 3 hrs pre-dose and 2 to 6 hrs post dose on Cycle 2, Day 1 (each cycle=28 days)
Trial Locations
- Locations (157)
Lkh-Univ. Klinikum Graz; Klinik Für Innere Medizin I
🇦🇹Graz, Austria
Medizinische Universität Wien; Univ.Klinik für Innere Medizin I
🇦🇹Wien, Austria
Complex Oncological Center - Plovdiv, EOOD
🇧🇬Plovdiv, Bulgaria
Clinica del Country
🇨🇴Bogota, Colombia
Oncomedica S.A.
🇨🇴Monteria, Colombia
British Columbia Cancer Agency (Bcca) - Vancouver Cancer Centre
🇨🇦Vancouver, British Columbia, Canada
MHAT Nadezhda
🇧🇬Sofia, Bulgaria
SHATO - Sofia
🇧🇬Sofia, Bulgaria
Turku Uni Central Hospital; Oncology Clinics
🇫🇮Turku, Finland
KYS Sadesairaala; Syopatautien poliklinikka
🇫🇮Kuopio, Finland
SHATOD Dr. Marko Antonov Markov-Varna, EOOD
🇧🇬Varna, Bulgaria
IASO General Hospital of Athens
🇬🇷Athens, Greece
Univ General Hosp Heraklion; Medical Oncology
🇬🇷Heraklion, Greece
Oncocenter Peru S.A.C.; Oncosalud
🇵🇪Lima, Peru
Hospital Garcia de Orta; Servico de Oncologia Medica
🇵🇹Almada, Portugal
IPO do Porto; Servico de Oncologia Medica
🇵🇹Porto, Portugal
Euroclinic Center of Oncology SRL
🇷🇴Iasi, Romania
Institute for Onc/Rad Serbia
🇷🇸Belgrade, Serbia
Mackay Memorial Hospital; Dept of Surgery
🇨🇳Taipei, Taiwan
Mercy Hospitals East Communities d/b/a Mercy Hospital St. Louis
🇺🇸Saint Louis, Missouri, United States
Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital
🇺🇸Marietta, Georgia, United States
Liverpool Hospital; Cancer Therapy Centre
🇦🇺Liverpool, New South Wales, Australia
Macquarie University Hospital
🇦🇺Macquarie Park, New South Wales, Australia
Sunshine Hospital; Oncology Research
🇦🇺St Albans, Victoria, Australia
Oregon Health & Science University; Knight Cancer Institute, Community Hematology Oncology
🇺🇸Beaverton, Oregon, United States
Memorial Sloan-Kettering; Cancer Center
🇺🇸Commack, New York, United States
St John of God Murdoch Hospital; Oncology West
🇦🇺Murdoch, Western Australia, Australia
Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering; at Westchester
🇺🇸Harrison, New York, United States
University Hospital; Oncology and Radiotherapy
🇨🇿Hradec Kralove, Czechia
Memorial Sloan Kettering Cancer Center
🇺🇸New York, New York, United States
John Theurer Cancer Ctr at Hackensack Univ Medical Ctr
🇺🇸Hackensack, New Jersey, United States
Centre Georges François Leclerc; Service Pharmacie, Bp 77980
🇫🇷Dijon, France
Newcastle Mater Misericordiae Hospital; Oncology
🇦🇺Waratah, New South Wales, Australia
Fakultni nemocnice Olomouc; Onkologicka klinika
🇨🇿Olomouc, Czechia
Centre Jean Perrin; Hopital De Semaine
🇫🇷Clermont-Ferrand, France
Grand River Hospital
🇨🇦Kitchener, Ontario, Canada
Inje university Haeundae Paik Hospital
🇰🇷Busan, Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
Sunnybrook Health Science Centre
🇨🇦Toronto, Ontario, Canada
Hospital Du Saint-Sacrement
🇨🇦Quebec City, Quebec, Canada
Jiangsu Cancer Hospital
🇨🇳Nanjing City, China
Alexandras General Hospital of Athens; Oncology Department
🇬🇷Athens, Greece
Hopital Prive Drome Ardeche; Chir 2A 2B
🇫🇷Guilherand Granges, France
Praxisklinik Krebsheilkunde für Frauen / Brustzentrum (Dres. Kittel/Klare)
🇩🇪Berlin, Germany
Vseobecna fakultni nemocnice v Praze
🇨🇿Praha 2, Czechia
Ulsan University Hosiptal
🇰🇷Ulsan, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
CHD Vendée
🇫🇷La Roche Sur Yon, France
Hopital Dupuytren; Oncologie Medicale
🇫🇷Limoges, France
Chungbuk National University Hospital
🇰🇷Cheongju-si, Korea, Republic of
Iem-Fucam
🇲🇽D.f., Mexico
Trakya University Medical Faculty Research And Practice Hospital Medical Oncology Department
🇹🇷Edirne, Turkey
Hospital Universitario Miguel Servet; Servicio Oncologia
🇪🇸Zaragoza, Spain
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Korea University Anam Hospital
🇰🇷Seoul, Korea, Republic of
Hospital San Jose Del Tec. de Monterrey; Oncology
🇲🇽Monterrey, Mexico
Instituto Nacional de Enfermedades Neoplasicas
🇵🇪Lima, Peru
Ege Uni Medical Faculty; Oncology Dept
🇹🇷Izmir, Turkey
IPO de Lisboa; Servico de Oncologia Medica
🇵🇹Lisboa, Portugal
Regional Clinical Oncology Dispensary; Surgery Dept, Thoracic
🇷🇺Arkhangelsk, Russian Federation
Istanbul Uni Cerrahpasa Medical Faculty Hospital; Medical Oncology
🇹🇷Istanbul, Turkey
Hospital ClÃnic i Provincial; Servicio de HematologÃa y OncologÃa
🇪🇸Barcelona, Spain
Hospital Universitario de Canarias;servicio de Oncologia
🇪🇸La Laguna, Tenerife, Spain
Hospital Ramon y Cajal; Servicio de Oncologia
🇪🇸Madrid, Spain
Institut of Oncology Al. Trestioreanu Bucharest; Oncology Department
🇷🇴Bucuresti, Romania
Oncology Center Sf. Nectarie
🇷🇴Craiova, Romania
Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology
🇨🇳Taipei City, Taiwan
Hospital de Cruces; Servicio de Oncologia
🇪🇸Bilbao, Vizcaya, Spain
VETERANS GENERAL HOSPITAL; Department of General Surgery
🇨🇳Taipei, Taiwan
Department of Surgery, King Chulalongkorn Memorial Hospital
🇹ðŸ‡Bangkok, Thailand
Hospital de Santa Maria; Servico de Oncologia Medica
🇵🇹Lisboa, Portugal
Moscow City Oncology Hospital #62
🇷🇺Moscovskaya Oblast, Moskovskaja Oblast, Russian Federation
Sodersjukhuset; Onkologkliniken
🇸🇪Stockholm, Sweden
Fundación IVO
🇪🇸Valencia, Spain
HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia
🇪🇸Madrid, Spain
the First Hospital of Jilin University
🇨🇳Changchun, China
Jilin Cancer Hospital
🇨🇳Changchun, China
Fudan University Shanghai Cancer Center
🇨🇳Shanghai City, China
Zhejiang Cancer Hospital
🇨🇳Zhejiang, China
Mater Hospital; Oncology
🇦🇺Brisbane, Queensland, Australia
Tiroler Landeskrankenanstalten Ges.M.B.H.; Abt. Für Gynäkologie
🇦🇹Innsbruck, Austria
Ordensklinikum Linz Barmherzige Schwestern; Abt. fur Innere Medizin 1
🇦🇹Linz, Austria
University Clinical Center of the Republic of Srpska
🇧🇦Banja Luka, Bosnia and Herzegovina
Clinic of Oncology, University Clinical Center Sarajevo
🇧🇦Sarajevo, Bosnia and Herzegovina
Arizona Oncology Associates, P.C.
🇺🇸Tucson, Arizona, United States
Georgia Cancer Specialists - Northside
🇺🇸Atlanta, Georgia, United States
Ingalls Hospital
🇺🇸Harvey, Illinois, United States
Maryland Oncology Hematology
🇺🇸Rochville, Maryland, United States
Dana Farber Can Ins
🇺🇸Boston, Massachusetts, United States
Memorial Sloan Kettering Nassau
🇺🇸Uniondale, New York, United States
Institut régional du Cancer Montpellier
🇫🇷Montpellier, France
Institut Curie; Oncologie Medicale
🇫🇷Paris, France
Ch Lyon Sud; Onco Secteur Jules Courmont
🇫🇷Pierre Benite, France
Pole de Cancerologie Prive Strasbourgeois
🇫🇷Strasbourg, France
Centre Alexis Vautrin; Oncologie Medicale
🇫🇷Vandoeuvre-les-nancy, France
Hochwaldkrankenhaus; Abt.Gynäkologie Geburtshilfe u.Senologie
🇩🇪Bad Nauheim, Germany
Onkologische Schwerpunktpraxis Kurfürstendamm
🇩🇪Berlin, Germany
Universitätsklinikum Essen; Zentrum Für Frauenheilkunde
🇩🇪Essen, Germany
Kooperatives Mammazentrum Hamburg Krankenhaus Jerusalem
🇩🇪Hamburg, Germany
Klinikum Mutterhaus der Borromäerinnen, Innere Medizin I
🇩🇪Trier, Germany
Klinikum der Universität München; Frauenklinik - Onkologie II
🇩🇪München, Germany
University Hospital of Patras Medical Oncology
🇬🇷Patras, Greece
Severance Hospital, Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
Clinica Internacional, Sede San Borja; Unidad de Investigacion de ClÃnica Internacional
🇵🇪Lima, Peru
Szpital Uniwersytecki w Krakowie, Oddział Kliniczny Kliniki Onkologii
🇵🇱Kraków, Poland
Hospital da Luz; Departamento de Oncologia Medica
🇵🇹Lisboa, Portugal
Prof. Dr. I. Chiricuta Institute of Oncology
🇷🇴Cluj Napoca, Romania
Ivanovo Regional Oncology Dispensary
🇷🇺Ivanovo, Russian Federation
S-Pb clinical scientific practical center of specialized kinds of medical care (oncological)
🇷🇺Saint-Petersburg, Russian Federation
Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia
🇪🇸Santiago de Compostela, LA Coruña, Spain
Centro Oncologico MD Anderson Internacional; Servicio de Oncologia
🇪🇸Madrid, Spain
Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc
🇹ðŸ‡Bangkok, Thailand
Istituto Nazionale Tumori Irccs Fondazione g. PASCALE;U.O.C. Oncologia Medica Senologica
🇮🇹Napoli, Campania, Italy
ARCISPEDALE S. MARIA NUOVA - REGGIO EMILIA; Struttura Semplice Coordinamento Breast Unit Integrata
🇮🇹Reggio Emilia, Emilia-Romagna, Italy
A.O. Universitaria S. Maria Della Misericordia Di Udine; Oncologia
🇮🇹Udine, Friuli-Venezia Giulia, Italy
Istituto Europeo Di Oncologia
🇮🇹Milano, Lombardia, Italy
Centro Catanese Di Oncologia; Oncologia Medica
🇮🇹Catania, Sicilia, Italy
Azienda Ospedaliero-Universitaria Careggi; SOD Radioterapia
🇮🇹Firenze, Toscana, Italy
Azienda USL 9 Grosseto; Dipartimento Politiche del Farmaco
🇮🇹Grosseto, Toscana, Italy
Azienda usl 5 Di Pisa-Ospedale Di Pontedera;U.O. Oncologia
🇮🇹Pontedera, Toscana, Italy
Uni Hospital Linkoeping; Dept. of Oncology
🇸🇪Linköping, Sweden
Akademiska sjukhuset, Onkologkliniken
🇸🇪Uppsala, Sweden
Baskent University Adana Dr. Turgut Noyan Practice and Research Hospital; Medical Oncology
🇹🇷Adana, Turkey
Hacettepe Uni Medical Faculty Hospital; Oncology Dept
🇹🇷Sihhiye/Ankara, Turkey
Hospital Universitari Vall d'Hebron
🇪🇸Barcelona, Spain
National Taiwan Uni Hospital; General Surgery
🇨🇳Taipei, Taiwan
MSKCC at Basking Ridge
🇺🇸Basking Ridge, New Jersey, United States
Arizona Oncology
🇺🇸Tucson, Arizona, United States
Austin Hospital; Medical Oncology
🇦🇺Heidelberg, Victoria, Australia
McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology
🇨🇦Montreal, Quebec, Canada
Euromedical General Clinic of Thessaloniki; Oncology Department
🇬🇷Thessaloniki, Greece
Papageorgiou General Hospital; Medical Oncology
🇬🇷Thessaloniki, Greece
Oaxaca Site Management Organization
🇲🇽Oaxaca, Mexico
Medisch Centrum Alkmaar
🇳🇱Alkmaar, Netherlands
Ziekenhuis Rijnstate
🇳🇱Arnhem, Netherlands
Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie Klinika Nowotworów Piersi i Chirurgii
🇵🇱Warszawa, Poland
Clinical Oncology Dispensary of Ministry of Health of Tatarstan
🇷🇺Kazan, Russian Federation
State Inst. Of Healthcare Orenburg Regional Clinical Oncology Dis
🇷🇺Orenburg, Russian Federation
AZ. Usll12 Veneziana-Ospedale Dell'angelo;Oncologia Medica
🇮🇹Mestre, Veneto, Italy
IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A
🇮🇹Genova, Liguria, Italy
Instituto Nacional De Cancerologia; Oncology; Tumores Mamarios
🇲🇽Distrito Federal, Mexico
Consultorio de Medicina Especializada; Dentro de Condominio San Francisco
🇲🇽Mexico City, Mexico
National Cancer Center
🇰🇷Goyang-si, Korea, Republic of
Instituto Regional de Enfermedades Neoplasicas - IREN Norte
🇵🇪Trujillo, Peru
Bialostockie Centrum Onkologii; Oddzial Onkologii Klinicznej
🇵🇱Bialystok, Poland
Centrum Onkologii w Bydgoszczy; Oddzial Kliniczny Onkologii
🇵🇱Bydgoszcz, Poland
Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii
🇵🇱Gdansk, Poland
Przychodnia Lekarska KOMED, Roman Karaszewski
🇵🇱Konin, Poland
Woj.Wielospecjalistyczne Centrum Onkologii i Traumatologii; Oddz.Hematologii Pododz.Chemioterapii
🇵🇱Lodz, Poland
Centrum Onkologii Ziemi LUBELSKIEJ im. Sw Jana z Dukli, I oddz. Chemioterapii
🇵🇱Lublin, Poland
Zachodniopomorskie Centrum Onkologii, Osrodek Innowacyjnosci, Rozwoju i Badan Klinicznych
🇵🇱Szczecin, Poland
Wojewodzki Szpital Specjalistyczny; Osrodek Badawczo-Rozwojowy, Oddzial Chemioterapii
🇵🇱Wroclaw, Poland
Maharaj Nakorn Chiang Mai Hospital; Department of Surgery/Head Neck and Breast Unit; Clinical Trial
🇹ðŸ‡Chiang Mai, Thailand
The Ottawa Hospital Cancer Centre; Oncology
🇨🇦Ottawa, Ontario, Canada
Cross Cancer Institute
🇨🇦Edmonton, Alberta, Canada
Hospital Universitario Puerta de Hierro; Servicio de Oncologia
🇪🇸Majadahonda, Madrid, Spain
Pinnacle Health
🇺🇸Harrisburg, Pennsylvania, United States